← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
INSMED Inc: Revenue grew 66.7% to $606M from $364M. Net loss widened to $1.277B from $914M. Free-cash outflow widened to $968M from $706M. Operating margin expanded 3588 bps to -205.59%. INSMED Inc's annual comparison also shows free cash flow declined despite revenue growth; margins improved while free cash flow declined; the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 66.7% to $606M from $364MOK
- Profitability — Net loss widened to $1.277B from $914MWatch
- Cash flow — Free-cash outflow widened to $968M from $706MWatch
- Margins — Operating margin expanded 3588 bps to -205.59%OK
- Accounting — Distress-range screen needs contextWatch
- Insiders — 0 purchases and 74 salesWatch
Business
With respect to CF, we are obligated to use commercially reasonable efforts to develop, obtain regulatory and reimbursement approval, market and sell ARIKAYCE in two or more major European countries, as well as to achieve certain milestones specified in the licensing agreement.
Where the revenue comes from
Fiscal 2025, as INSMED Inc reports it. History and quarterly detail are in the app.
- ARIKAYCE$433.8M
- BRINSUPRI$172.7M
Leadership changes
From INSMED Inc's own filings, the day they're filed.
- J. Drayton Wise · Chief Commercial Officer · departure
- Insmed Incorporated · Chief Commercial Officer · departure
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about INSMED Inc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.